Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more
Market Cap & Net Worth: Ultragenyx Pharmaceutical Inc. (0LIF)
Ultragenyx Pharmaceutical Inc. (LSE:0LIF) has a market capitalization of $1.12 Billion ($1.12 Billion) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #4884 globally and #137 in its home market, demonstrating a -1.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ultragenyx Pharmaceutical Inc.'s stock price $22.18 by its total outstanding shares 50579600 (50.58 Million).
Ultragenyx Pharmaceutical Inc. Market Cap History: 2026 to 2026
Ultragenyx Pharmaceutical Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $1.12 Billion to $1.12 Billion (0.00% CAGR).
Ultragenyx Pharmaceutical Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ultragenyx Pharmaceutical Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0LIF by Market Capitalization
Companies near Ultragenyx Pharmaceutical Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Ultragenyx Pharmaceutical Inc. by market ranking:
- TMBThanachart Bank Public Company Limited (F:NVPJ): Ranked #4875 globally with a market cap of $2.07 Billion USD ( €2.02 Billion EUR).
- Henan Yuguang Gold & Lead Co Ltd (SHG:600531): Ranked #4876 globally with a market cap of $2.07 Billion USD ( CN¥15.18 Billion CNY).
- Hanwha Chemical Corp Pref (KO:009835): Ranked #4885 globally with a market cap of $2.06 Billion USD ( ₩3.02 Trillion KRW).
- Bank of Guiyang Co Ltd (SHG:601997): Ranked #4886 globally with a market cap of $2.06 Billion USD ( CN¥15.13 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #4875 | TMBThanachart Bank Public Company Limited | F:NVPJ | $2.07 Billion | €0.06 |
| #4876 | Henan Yuguang Gold & Lead Co Ltd | SHG:600531 | $2.07 Billion | CN¥15.40 |
| #4885 | Hanwha Chemical Corp Pref | KO:009835 | $2.06 Billion | ₩28150.00 |
| #4886 | Bank of Guiyang Co Ltd | SHG:601997 | $2.06 Billion | CN¥5.90 |
Ultragenyx Pharmaceutical Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Ultragenyx Pharmaceutical Inc.'s market cap moved from $1.12 Billion to $ 1.12 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ultragenyx Pharmaceutical Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.12 Billion USD |
| MoneyControl | $1.12 Billion USD |
| MarketWatch | $1.12 Billion USD |
| marketcap.company | $1.12 Billion USD |
| Reuters | $1.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.